Investing.com - Marinus Pharma (NASDAQ: MRNS) reported second quarter EPS of $-0.61, $0.11 better than the analyst estimate of $-0.72. Revenue for the quarter came in at $6.08M versus the consensus estimate of $5.71M.
Marinus Pharma's stock price closed at $8.68. It is down -1.14% in the last 3 months and up 50.43% in the last 12 months.
Marinus Pharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Marinus Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Marinus Pharma's Financial Health score is "fair performance".
Check out Marinus Pharma's recent earnings performance, and Marinus Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar